Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

liraglutide

- PMLiVE

Novo Nordisk creates all-diabetes pro-cycling team

Team Novo Nordisk includes more than 100 cyclists, triathletes and runners with diabetes

Sanofi reception

Sanofi has 65 new compounds in development, says R&D chief

Elias Zerhouni to showcase pharma company's pipeline, promises costs will be rigorously managed

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

- PMLiVE

Hanspeter Spek to retire from Sanofi

President of global operations will step down after 18 years at the pharma company

- PMLiVE

Sanofi boosts animal health business with Dosch acquisition

Opens door to €350m market for company’s Merial division

Sanofi reception

Blow for Sanofi as EMA turns down cholesterol drug Kynamro

Points to safety concerns related to liver toxicity and cardiovascular events

- PMLiVE

Sanofi picks corporate voice for new blogging venture

Pharma company's US arm goes beyond discussing diabetes

- PMLiVE

Novo launches haemophilia tracking app

Will compete with similar apps from Pfizer, Baxter

- PMLiVE

Novo Nordisk says Ryzodeg nears Japanese approval

Combination of Tresiba and NovoRapid expected to compete with Sanofi’s Lantus

- PMLiVE

Sanofi takes anti-counterfeiting message to the skies

Hopes to reach four million passengers with Air France film

Sanofi reception

Sanofi signs $900m allergy collaboration with Selecta

Companies will develop three immunotherapies targeting different allergens

Kala Pharma appoints Fovea founder Bernard Gilly to board

He previously formed the company that became Sanofi’s ophthalmology business

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links